Antibiotic Therapy Guidelines

Introduction to Antibiotic Therapy

The European Respiratory Society and the American Thoracic Society provide guidelines for the management of community-acquired pneumonia (CAP), including recommendations for antibiotic therapy 1, 2

The European Respiratory Society recommends switching from parenteral to oral antibiotics by day 3 of admission if the patient is clinically stable, as supported by the Infectious Diseases Society of America with a strength of evidence rated as moderate 1, 3
Patients can be switched from IV to oral therapy when they are hemodynamically stable, clinically improving, can ingest medications, and have a normally functioning gastrointestinal tract, as recommended by the IDSA with a strength of evidence rated as moderate 3

The patient should be considered for follow-up CXR in 4-6 weeks if they have risk factors for delayed radiographic clearing, such as older age, COPD, alcoholism, or other chronic illness, as recommended by the American Thoracic Society 2
Complete radiographic resolution may take 4-12 weeks, especially in older patients or those with comorbidities, as supported by the European Respiratory Society 2
Regular monitoring of vital signs, mental status, and oxygen saturation, as well as nutritional support in prolonged illness, are crucial components of supportive care, as recommended by the British Thoracic Society with a strength of evidence rated as high 4

If the patient develops worsening symptoms, such as recrudescent fever or increasing dyspnea, after switching to oral therapy, they should be reevaluated for resistant organisms, parapneumonic effusion or empyema, or non-infectious causes, as recommended by the European Respiratory Society 1
Clinical response assessment indicates that fever should resolve within 2-3 days after starting antibiotics, and treatment failure is indicated by persistent fever beyond 3 days, worsening respiratory symptoms, or progression of pulmonary infiltrates, as recommended by the European Respiratory Society 5

The American Thoracic Society recommends beta-lactam (ceftriaxone, cefotaxime, ampicillin-sulbactam) plus a macrolide (azithromycin) for patients without comorbidities or risk factors for drug-resistant S. pneumoniae (DRSP) 2
The Infectious Diseases Society of America recommends amoxicillin-clavulanate as a first-line option for suspected pneumococcal pneumonia, especially if beta-lactamase producers are suspected, with a strength of evidence rated as strong 6
Respiratory fluoroquinolones are recommended for patients with beta-lactam allergies, as suggested by the Infectious Diseases Society of America 3
The following treatment options are recommended for CAP caused by specific pathogens:

Pathogen	Treatment Options
Streptococcus pneumoniae	Beta-lactams (amoxicillin, cefotaxime, ceftriaxone) [4, 3, 7, 8]
Mycoplasma pneumoniae	Macrolide (azithromycin preferred) [4, 1, 7, 8]
Legionella spp.	Levofloxacin (preferred), moxifloxacin, or macrolide ± rifampicin [4, 1, 7, 8]
Chlamydophila pneumoniae	Doxycycline, macrolide, levofloxacin, or moxifloxacin [4, 1, 7, 8]
Coxiella burnetii	Doxycycline, levofloxacin, or moxifloxacin [1]
Pseudomonas	Antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin/levofloxacin or an aminoglycoside plus azithromycin [3]
CA-MRSA	Vancomycin or linezolid should be added to standard therapy, as recommended by the IDSA [3]

The American Thoracic Society recommends standard therapy for 7-10 days total for severe CAP or specific pathogens 2
The American Thoracic Society (ATS) recommends prescribing antibiotics for CAP for a minimum of 5 days, with extension of therapy guided by validated measures of clinical stability, including resolution of vital sign abnormalities, ability to eat, and normal mentation, with a strength of evidence rated as high 9, 8
For standard uncomplicated CAP, a treatment duration of 5 days is recommended when clinical stability is achieved, as suggested by the IDSA and ATS, with a strength of evidence rated as moderate 9, 8
For CAP caused by MRSA or Pseudomonas aeruginosa, a treatment duration of 7 days is recommended, as suggested by the IDSA and ATS, with a strength of evidence rated as low 8
De-escalation of antibiotic therapy is recommended after 48-72 hours if no evidence of bacterial superinfection is found, and clinical response is adequate, as supported by the IDSA, with a strength of evidence rated as moderate 10
Discontinuation of antibiotic therapy is recommended if no evidence of bacterial infection is found, with a minimum duration of 5 days and the patient being afebrile for 48-72 hours before discontinuation, as recommended by the IDSA, with a strength of evidence rated as low 10, 11, 3

Oxygen therapy should be provided to maintain SaO₂ >92%, and intravenous fluids should be administered if dehydrated, as recommended by the British Thoracic Society 4
Consider hospital admission if the patient has severe respiratory failure, as indicated by a respiratory rate >30 breaths/min, or a PaO₂/FiO₂ <200 mmHg, particularly for COPD patients, as recommended by the European Respiratory Society 5

Doxycycline has been shown to be cost-effective compared to levofloxacin for hospitalized patients with non-severe CAP, though concerns exist about potential resistance development 2
Common errors to avoid in pneumonia management include inadequate initial coverage, delayed switch from IV to oral, inappropriate duration, failure to recognize treatment failure, and overuse of antibiotics, as recommended by the IDSA and the American College of Physicians, with a strength of evidence rated as high 12, 4, 7
Overuse of antibiotics should be avoided by using narrow-spectrum antibiotics when a pathogen is identified, as recommended by the IDSA, with a strength of evidence rated as moderate 3